Department of Biomedical Engineering, McGill Universit, Montréal, Québec, Canada.
The Research Institute of McGill University Health Centre, Montréal, Québec, Canada.
Diabetes Obes Metab. 2021 Jun;23(6):1272-1281. doi: 10.1111/dom.14335. Epub 2021 Feb 28.
To assess whether adding empagliflozin to closed-loop automated insulin delivery could reduce the need for carbohydrate counting in type 1 diabetes (T1D) without worsening glucose control.
In an open-label, crossover, non-inferiority trial, 30 adult participants with T1D underwent outpatient automated insulin delivery interventions with three random sequences of prandial insulin strategy days: carbohydrate counting, simple meal announcement (no carbohydrate counting) and no meal announcement. During each sequence of prandial insulin strategies, participants were randomly assigned empagliflozin (25 mg/day) or not, and crossed over to the comparator. Mean glucose for carbohydrate counting without empagliflozin (control) was compared with no meal announcement with empagliflozin (in the primary non-inferiority comparison) and simple meal announcement with empagliflozin (in the conditional primary non-inferiority comparison).
Participants were aged 40 ± 15 years, had 27 ± 15 years diabetes duration and HbA1c of 7.6% ± 0.7% (59 ± 8 mmol/mol). The system with no meal announcement and empagliflozin was not non-inferior (and thus reasonably considered inferior) to the control arm (mean glucose 10.0 ± 1.6 vs. 8.5 ± 1.5 mmol/L; non-inferiority p = .94), while simple meal announcement and empagliflozin was non-inferior (8.5 ± 1.4 mmol/L; non-inferiority p = .003). Use of empagliflozin on the background of automated insulin delivery with carbohydrate counting was associated with lower mean glucose, corresponding to a 14% greater time in the target range. While no ketoacidosis was observed, mean fasting ketones levels were higher on empagliflozin (0.22 ± 0.18 vs. 0.13 ± 0.11 mmol/L; p < .001).
Empagliflozin added to automated insulin delivery has the potential to eliminate the need for carbohydrate counting and improves glycaemic control in conjunction with carbohydrate counting, but does not allow for the elimination of meal announcement.
评估在 1 型糖尿病(T1D)患者中,添加恩格列净是否可以在不恶化血糖控制的情况下减少对碳水化合物计数的需求。
在一项开放标签、交叉、非劣效性试验中,30 名成年 T1D 患者接受了门诊自动胰岛素输注干预,采用三种随机的餐前胰岛素策略日序列:碳水化合物计数、简单餐宣告(无需碳水化合物计数)和无餐宣告。在每个餐前胰岛素策略序列中,参与者被随机分配接受恩格列净(25mg/天)或不接受,并交叉至对照组。在主要非劣效性比较中,无恩格列净的碳水化合物计数的平均血糖(对照)与有恩格列净的无餐宣告(主要条件非劣效性比较)进行比较,与有恩格列净的简单餐宣告(主要条件非劣效性比较)进行比较。
参与者年龄为 40±15 岁,糖尿病病程 27±15 年,HbA1c 为 7.6%±0.7%(59±8mmol/mol)。无餐宣告和恩格列净系统与对照组相比不具有非劣效性(因此合理地认为是劣效性)(平均血糖 10.0±1.6 与 8.5±1.5mmol/L;非劣效性 p=0.94),而简单餐宣告和恩格列净具有非劣效性(8.5±1.4mmol/L;非劣效性 p=0.003)。在自动胰岛素输注的背景下使用恩格列净联合碳水化合物计数,平均血糖降低,相应地目标范围内的时间增加了 14%。虽然没有观察到酮症酸中毒,但恩格列净组的空腹酮体水平更高(0.22±0.18 与 0.13±0.11mmol/L;p<0.001)。
在自动胰岛素输注中添加恩格列净有可能消除对碳水化合物计数的需求,并在联合碳水化合物计数的情况下改善血糖控制,但不能消除餐宣告。